Abstract

BackgroundBAFF production is increased in IBD patients. However, the specific role of BAFF in IBD is still uncovered. This study aimed to investigate the expression and function of BAFF in experimental colitis and the potential mechanisms.MethodsBAFF levels in the serum and colon tissues were measured by ELISA in DSS-induced colitis mice. Mouse-derived BAFF antibody was administered in DSS mice. The changes of body weight, disease activity index (DAI) scores, colon length, spleen weight, histopathological damage, inflammatory indicators, NF-κB signaling, and NLRP3 inflammasome were assayed in DSS mice and control. LPS-primed RAW264.7 cells and bone marrow derived macrophages (BMDMs) were treated with BAFF blockage and recombinant mouse BAFF. Inflammatory associated cytokines, NLRP3 inflammasomes and NF-κB signaling were detected among groups.ResultsBAFF production was elevated systemically and locally in colitis mice. BAFF blockade improved the body weight loss, DAI scores, colon length, spleen weight, and histopathological damage in colitis mice. Immunoflurescence analysis revealed that elevated macrophages in mucosal lamina propria were the primary source of BAFF in the colon. NLRP3 inflammasome and NF-κB signaling pathway activation were dramatically inhibited in DSS mice treated with BAFF blockage. In LPS-primed RAW264.7 cells/BMDMs, BAFF blockade decreased the activation of NLRP3 inflammasome (NLPR3, ASC, cleaved IL-1β, cleaved caspase 1) via inhibiting NF-κB signaling pathway. Moreover, LPS synergizes with BAFF to promote inflammatory factor secretion and expression of NF-κB signaling pathway in RAW264.7 cells.ConclusionsThese results suggested that BAFF blockade protected against colitis partially by relieving inflammation, inhibiting intestinal NLRP3 inflammasome and NF-κB signaling pathway from macrophages. BAFF plays an important role in inflammation regulation in IBD, thus providing a novel idea for further research on colitis and experimental evidences for novel potential therapeutic target in IBD.

Highlights

  • Inflammatory bowel disease (IBD) is a chronic disorder characterized by life-long treatment and incurable idiopathic intestinal inflammation, affecting the health and well-being of patients significantly [1]

  • Our previous study found that BAFF, a new biomarker for IBD, was strongly associated with IBD-related intestinal inflammation and that serum BAFF levels in patients with ulcerative colitis were strongly correlated with Mayo score and tumor necrosis factor (TNF)-a presented all strong positive correlations [8]

  • Immunofluorescence showed that BAFF+ cells in the colon of DSS mice remarkably increased compared with control mice with a distribution pattern in lamina propria infiltrating mononuclear cells, especially in macrophages (Figures 1C, D)

Read more

Summary

Introduction

Inflammatory bowel disease (IBD) is a chronic disorder characterized by life-long treatment and incurable idiopathic intestinal inflammation, affecting the health and well-being of patients significantly [1]. We detected increased expression of BAFF in serum and colon in IBD patients, with sensitivity, specificity and AUC of 88%, 100% and 0.936 in UC patients compared to irritable bowel syndrome (IBS) patients or healthy controls, respectively [8] Fodor in his latest study examined BAFF and fecal calprotectin in the stools of children with CD, children with UC, children with irritable bowel syndrome (IBS) and healthy children, discovered a significant increase in fecal BAFF concentration in group with IBD and a remarkable correlation between BAFF and fecal calprotectin [9]. These studies suggest that BAFF may be a new non-invasive biomarker for screening patients with IBD and potentially being an effective biological target. This study aimed to investigate the expression and function of BAFF in experimental colitis and the potential mechanisms

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call